FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036692211> ?p ?o ?g. }

• W3036692211 abstract "Abstract Background Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is incurable, with a median survival of only ~ 13 months. We have initiated the randomized placebo-controlled phase IIb study ALICE, evaluating PD-L1 blockade combined with immunogenic chemotherapy in mTNBC patients (n = 75). Intriguingly, the host immune response is strongly predictive for the effect of chemotherapy in mTNBC. In the ALICE trial, we release the brake on the immune response by use of atezolizumab, an inhibitory antibody against PD-L1. We utilize anthracyclines, shown to trigger the immune system, and low-dose cyclophosphamide, which has been reported to counter immunosuppressive cells. Methods ALICE is a randomized, double-blind, placebo-controlled exploratory phase II study evaluating the safety and efficacy of atezolizumab when combined with immunogenic chemotherapy in subjects with mTNBC. The trial will enroll 75 evaluable subjects, randomized 2:3 into two arms (A:B). The patients receive identical chemotherapy, i.e. pegylated liposomal doxorubicin (PLD 20 mg/m 2 intravenously every 2nd week) + cyclophosphamide (50 mg per day, first 2 weeks in each 4 week cycle). Patients in arm A receive placebo, while patients in arm B receive atezolizumab. The primary objectives are assessment of toxicity and progression-free survival. The secondary objectives include overall survival, tumor response rate, clinical benefit rate, patient reported outcomes, biomarkers and assessment of tumor-immune evolution during therapy. Discussion The question of how CI should be combined with chemotherapy, is a key challenge facing the field. There is a strong preclinical rationale for exploring if anthracyclines, which are considered to induce immunogenic cell death, synergize with PD-L1 blockade, and if low-dose cyclophosphamide counters tumor tolerance. However, the data from patients is as yet very limited, and the clinical evaluation of these hypotheses is among the key objectives in the ALICE trial. The study includes extensive biobanking and translational sub-projects, also addressing other clinically important questions. These analyses may uncover mechanisms of drug efficacy or tumor resistance, and identify biomarkers allowing personalized therapy. If the trial suggests acceptable safety of the ALICE therapy and provide a signal of clinical efficacy, further studies are warranted. Trial registration NCT03164993, May 24th 2017; https://clinicaltrials.gov/ct2/show/record/NCT03164993" @default.
• W3036692211 created "2020-06-25" @default.
• W3036692211 creator A5001565523 @default.
• W3036692211 creator A5003379784 @default.
• W3036692211 creator A5049510182 @default.
• W3036692211 creator A5057516617 @default.
• W3036692211 date "2020-06-23" @default.
• W3036692211 modified "2023-10-05" @default.
• W3036692211 title "ALICE: a randomized placebo-controlled phase II study evaluating atezolizumab combined with immunogenic chemotherapy in patients with metastatic triple-negative breast cancer" @default.
• W3036692211 cites W1254987090 @default.
• W3036692211 cites W1488880565 @default.
• W3036692211 cites W1973091654 @default.
• W3036692211 cites W1996464576 @default.
• W3036692211 cites W2023147685 @default.
• W3036692211 cites W2049553585 @default.
• W3036692211 cites W2081796577 @default.
• W3036692211 cites W2093424661 @default.
• W3036692211 cites W2166662937 @default.
• W3036692211 cites W2189073727 @default.
• W3036692211 cites W2252550602 @default.
• W3036692211 cites W2402636472 @default.
• W3036692211 cites W2438279308 @default.
• W3036692211 cites W2529484692 @default.
• W3036692211 cites W2576428049 @default.
• W3036692211 cites W2897422388 @default.
• W3036692211 cites W2944687997 @default.
• W3036692211 cites W2990398119 @default.
• W3036692211 cites W3006930853 @default.
• W3036692211 doi "https://doi.org/10.1186/s12967-020-02424-7" @default.
• W3036692211 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7310523" @default.
• W3036692211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32576225" @default.
• W3036692211 hasPublicationYear "2020" @default.
• W3036692211 type Work @default.
• W3036692211 sameAs 3036692211 @default.
• W3036692211 citedByCount "16" @default.
• W3036692211 countsByYear W30366922112020 @default.
• W3036692211 countsByYear W30366922112021 @default.
• W3036692211 countsByYear W30366922112022 @default.
• W3036692211 countsByYear W30366922112023 @default.
• W3036692211 crossrefType "journal-article" @default.
• W3036692211 hasAuthorship W3036692211A5001565523 @default.
• W3036692211 hasAuthorship W3036692211A5003379784 @default.
• W3036692211 hasAuthorship W3036692211A5049510182 @default.
• W3036692211 hasAuthorship W3036692211A5057516617 @default.
• W3036692211 hasBestOaLocation W30366922111 @default.
• W3036692211 hasConcept C121608353 @default.
• W3036692211 hasConcept C126322002 @default.
• W3036692211 hasConcept C142724271 @default.
• W3036692211 hasConcept C143998085 @default.
• W3036692211 hasConcept C168563851 @default.
• W3036692211 hasConcept C204787440 @default.
• W3036692211 hasConcept C27081682 @default.
• W3036692211 hasConcept C2775930923 @default.
• W3036692211 hasConcept C2775949291 @default.
• W3036692211 hasConcept C2776694085 @default.
• W3036692211 hasConcept C2776755627 @default.
• W3036692211 hasConcept C2777701055 @default.
• W3036692211 hasConcept C2780057760 @default.
• W3036692211 hasConcept C2780110267 @default.
• W3036692211 hasConcept C530470458 @default.
• W3036692211 hasConcept C71924100 @default.
• W3036692211 hasConceptScore W3036692211C121608353 @default.
• W3036692211 hasConceptScore W3036692211C126322002 @default.
• W3036692211 hasConceptScore W3036692211C142724271 @default.
• W3036692211 hasConceptScore W3036692211C143998085 @default.
• W3036692211 hasConceptScore W3036692211C168563851 @default.
• W3036692211 hasConceptScore W3036692211C204787440 @default.
• W3036692211 hasConceptScore W3036692211C27081682 @default.
• W3036692211 hasConceptScore W3036692211C2775930923 @default.
• W3036692211 hasConceptScore W3036692211C2775949291 @default.
• W3036692211 hasConceptScore W3036692211C2776694085 @default.
• W3036692211 hasConceptScore W3036692211C2776755627 @default.
• W3036692211 hasConceptScore W3036692211C2777701055 @default.
• W3036692211 hasConceptScore W3036692211C2780057760 @default.
• W3036692211 hasConceptScore W3036692211C2780110267 @default.
• W3036692211 hasConceptScore W3036692211C530470458 @default.
• W3036692211 hasConceptScore W3036692211C71924100 @default.
• W3036692211 hasFunder F4320307779 @default.
• W3036692211 hasFunder F4320310758 @default.
• W3036692211 hasFunder F4320335102 @default.
• W3036692211 hasIssue "1" @default.
• W3036692211 hasLocation W30366922111 @default.
• W3036692211 hasLocation W30366922112 @default.
• W3036692211 hasLocation W30366922113 @default.
• W3036692211 hasLocation W30366922114 @default.
• W3036692211 hasOpenAccess W3036692211 @default.
• W3036692211 hasPrimaryLocation W30366922111 @default.
• W3036692211 hasRelatedWork W2034849620 @default.
• W3036692211 hasRelatedWork W2418436192 @default.
• W3036692211 hasRelatedWork W2534174115 @default.
• W3036692211 hasRelatedWork W3010740851 @default.
• W3036692211 hasRelatedWork W3091025601 @default.
• W3036692211 hasRelatedWork W3130663466 @default.
• W3036692211 hasRelatedWork W3189641543 @default.
• W3036692211 hasRelatedWork W4214554217 @default.
• W3036692211 hasRelatedWork W4229066420 @default.
• W3036692211 hasRelatedWork W4310834173 @default.
• W3036692211 hasVolume "18" @default.
• W3036692211 isParatext "false" @default.
• W3036692211 isRetracted "false" @default.

• next